Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 240

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor: Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain

Yu, Helena A., Tian, Shaozhou K., Drilon, Alexander E., Borsu, Laetitia, Riely, Gregory J., Arcila, Maria E., Ladanyi, Marc·2015·JAMA Oncology

Abstract

EGFR-mutant lung cancers represent a paradigm for the use of tyrosine kinase inhibitors (TKIs) to treat molecular subsets of cancer, with randomized trials demonstrating the efficacy of first-generation, reversible epidermal growth factor receptor (EGFR) TKIs. However, acquired resistance invariably develops, and rebiopsy of patients with clinical progression has elucidated EGFR T790M mutation as the major resistance mechanism.1 To address this clinical challenge, third-generation pyrimidine-based EGFR TKIs have been designed to have selectivity for EGFR T790M over wild-type EGFR.2 They form a covalent bond with cysteine 797 in the adenosine triphosphate–binding cleft. Early-phase clinical trials have demonstrated their efficacy in patients with double-mutant tumors (EGFR L858R/T790M and ex19del/T790M) and acquired resistance to first-generation EGFR inhibitors.3 Specificity for EGFR T790M may be the result of hydrophobic interactions between the bulky methionine moiety of EGFR T790M and these pyrimidine-based drugs. Mechanisms of resistance to these third-generation EGFR TKIs have been identified in preclinical in vitro models, but none have so far been identified in patients. Mutations at the EGFR C797 codon, located within the kinase-binding site, are a predicted resistance mechanism to irreversible EGFR inhibitors also confirmed in vitro.4 Loss of the potential for covalent bond formation at position 797 by the missense mutation C797S results in a markedly reduced cellular potency of this class of TKIs.5 Interestingly, an analogous cysteine-to-serine mutation is a mechanism of resistance to the irreversible Bruton tyrosine kinase inhibitor ibrutinib in patients with chronic lymphocytic leukemia.6

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/jamaoncol.2015.1066

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 240

Metadata

Authors
Yu, H. A., Tian, S. K., Drilon, A. E., Borsu, L., Riely, G. J., Arcila, M. E., & Ladanyi, M.
Venue
JAMA Oncology
Published
2015-10-01
Volume
1
Issue
7
Pages
982
ISSN
2374-2437 (ISSN-L)
OpenAlex
W1584059175
Cited by
240
References
2
FWCI
25.45
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor: Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain. https://app.cochat.ai/papers/10.1001/jamaoncol.2015.1066
The paper
Yu, H. A., Tian, S. K., Drilon, A. E., Borsu, L., Riely, G. J., Arcila, M. E., & Ladanyi, M. (2015). Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor: Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain. JAMA Oncology. https://doi.org/10.1001/jamaoncol.2015.1066

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.